Policy & Regulation
Symic Bio finalises USD11m investment
26 April 2019 - Biopharmaceutical company Symic Bio revealed on Thursday the completion of financings led by Cell Innovation Partners (CIP), a healthcare venture fund started by ReproCELL and Shinsei ...
Stealth BioTherapeutics concludes patient enrolment in PMM study
26 April 2019 - Biotechnology company Stealth BioTherapeutics (NASDAQ:MITO) said on Thursday that it has completed the enrolment of patients with primary mitochondrial myopathy in its MMPOWER-3 (SPIMM...
Teva Pharmaceutical to halt fremanezumab's ENFORCE clinical development program
26 April 2019 - Israel-based Teva Pharmaceutical Industries is halting an ongoing clinical development program of its humanised monoclonal antibody fremanezumab in cluster headaches due to futility, i...
Gencove awarded Phase I SBIR grant to validate polygenic risk score estimation from low-pass sequencing
26 April 2019 - Genomic data company Gencove disclosed on Thursday that it has received a Phase I grant from the National Human Genome Research Institute under the auspices of the Small Business Innov...
Bausch Health Companies Inc wins US FDA approval for DUOBRII Lotion 0.01%/0.045% for treating plaque psoriasis in adults
26 April 2019 - Healthcare company Bausch Health Companies Inc (NYSE/TSX:BHC) and its Ortho Dermatologics dermatology business reported on Thursday the receipt of approval from the US Food and Drug Ad...
X4 Pharmaceuticals Names Kelley as Chief Medical Officer
26 April 2019 - - US-based clinical-stage biopharmaceutical company X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) has appointed E. Lynne Kelley, M.D., FACS, as the company's chief medical officer, the ...